Notizie e Video - ORION CLASS B

ORION CORPORATION PRESS RELEASE 15 OCTOBER 2024 at 9.00 EEST Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024 Orion will publish Interim Report for January–September 2024 on Tuesday, 29 October 2024 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and a conference call for analysts,...

ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion’s collaboration partner Bayer today announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in patients with metastatic...

ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2024 at 10.00 a.m. EEST Orion’s near-term climate targets approved by the Science Based Targets initiative Orion Corporation is proud to announce that the Science Based Targets initiative (SBTi) has validated our near-term science-based targets. This means that our greenhouse gas (GHG) emissions reduction targets align with the latest climate science to limit global warming to 1.5°C above pre-industrial levels. Orion Corporation commits to reduce...

ORION CORPORATION INVESTOR NEWS 26 SEPTEMBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster Orion’s collaboration partner Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of...

ORION CORPORATION PRESS RELEASE 25 SEPTEMBER 2024 at 15.00 EEST Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology Orion Corporation and Aitia, an AI-enabled biotechnology company and the leader in the development and application of Causal AI and "Digital Twins" to discover and develop new drugs, announced today that the companies have entered into agreement to create new Gemini Digital Twins to help in the fight against cancer. Cancer is a critical...

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 SEPTEMBER 2024 at 9.30 EEST 213,285 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 213,285 A shares have been converted into 213,285 B shares. The conversion has been entered into the Trade Register on 20 September 2024. The total number of shares in Orion Corporation is 141,134,278 which, after...

ORION CORPORATION PRESS RELEASE 16 SEPTEMBER 2024 at 11.30 EEST Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival (rPFS) compared to...

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 11 SEPTEMBER 2024 at 09:30 EEST Inside information: Orion upgrades full-year outlook for 2024 Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion’s product sales and royalty income has continued to grow faster than expected during the second half of 2024 and this good development is anticipated to continue during the remainder of the year. Due to these...

ORION CORPORATION MANAGERS’ TRANSACTIONS 22 AUGUST 2024 at 10.30 EEST Orion Corporation: Managers’ transactions – Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement...

ORION CORPORATION MANAGERS’ TRANSACTIONS 21 AUGUST 2024 at 18.45 EEST Orion Corporation: Managers’ transactions – Niclas Lindstedt Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement...

ORION CORPORATION MANAGERS’ TRANSACTIONS 20 AUGUST 2024 at 16.15 EEST Orion Corporation: Managers’ transactions – Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement...

ORION CORPORATION MANAGERS’ TRANSACTIONS 15 AUGUST 2024 at 15.30 EEST Orion Corporation: Managers’ transactions – Hao Pan Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name:...

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 14 AUGUST 2024 at 9.30 EEST 44,767 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 44,767 A shares have been converted into 44,767 B shares. The conversion has been entered into the Trade Register on 14 August 2024. The total number of shares in Orion Corporation is 141,134,278 which, after the...

ORION CORPORATION MANAGERS’ TRANSACTIONS 12 AUGUST 2024 at 15.30 EEST Orion Corporation: Managers’ transactions – Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement...

ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2024 8 AUGUST 2024 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2024 Net sales totalled EUR 636.7 (January–June 2023: 567.5) million Operating profit was EUR 121.8 (102.0) million Basic earnings per share were EUR 0.68 (0.57) Cash flow from operating activities per share was EUR 0.98 (0.27) The outlook for 2024 was upgraded after the reporting period on 1 July 2024: Net sales are estimated to be EUR 1,440 million to EUR...

ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 8 AUGUST 2024 at 9.45 EEST Orion Corporation’s financial reporting and Annual General Meeting in 2025 Orion Corporation will publish its Financial Statement Release 2024 on Tuesday, 25 February 2025. The publication dates of the Interim Reports and the Half-Year Financial Report in 2025 are as follows: Interim Report January-March 2025 Wednesday 23 April 2025 Half-Year Financial Report January-June 2025 Friday 18 July 2025 Interim...

ORION CORPORATION PRESS RELEASE 25 JULY 2024 at 11.00 EEST Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024 Orion will publish Half-Year Financial Report for January–June 2024 on Thursday, 8 August 2024 at approximately 12.00 noon EEST. The report and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and a conference call for...

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint Orion and Bayer’s Phase III ARANOTE trial meets primary endpoint, significantly increasing radiological progression-free survival (rPFS) with darolutamide + androgen deprivation therapy (ADT) compared to placebo plus...

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 1 JULY 2024 at 15:15 EEST Inside information: Orion upgrades full-year outlook for 2024 Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion and MSD (Merck & Co., Inc., Rahway, NJ, USA) have exercised the option to convert the co-development and co-commercialisation agreement with MSD regarding opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor,...

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 1 JULY 2024 at 15:15 EEST Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer Orion Corporation (“Orion”) and MSD (Merck & Co., Inc., Rahway, NJ, USA) today announced that notice has been provided of the mutual exercise of an option to convert the...